Physician profile
Jose F Montes
NPI 1811928716
$882,485.24
in general payments reported to CMS, 2019-2025
39 companies · $216K in 2025
The $216K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $35K · 2021: $59K · 2022: $98K · 2023: $150K · 2024: $221K · 2025: $216K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $407K · Travel and Lodging: $72K · Consulting Fee: $54K · Food and Beverage: $27K · Honoraria: $26K · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $407,437.00 |
| Travel and Lodging | $71,627.24 |
| Consulting Fee | $53,905.50 |
| Food and Beverage | $27,339.10 |
| Honoraria | $25,928.00 |
| Education | $142.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $333,207.77 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $201,691.56 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $131,797.65 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75,870.48 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $67,793.55 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $38,067.26 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $15,819.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,931.07 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $2,687.23 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Scientific Affairs, LLC | $1,652.30 | 2023-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $1,309.47 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,251.66 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Jazz Pharmaceuticals INC. | $852.02 | 2020-2023 | Xywav |
| Supernus Pharmaceuticals, INC. | $801.12 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $788.80 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Montes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.